Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma

Creative Commons License

Uckun F. M., Qazi S., DEMİRER T., Champlin R. E.

EBIOMEDICINE, cilt.39, ss.612-620, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 39
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.ebiom.2018.12.004
  • Dergi Adı: EBIOMEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.612-620
  • Anahtar Kelimeler: Personalized medicine, Multiple myeloma, Stem cell transplantation, Immuno-oncology, Immunotherapy, Biotherapy, CELL MATURATION ANTIGEN, TYROSINE KINASE, PLUS BORTEZOMIB, DEXAMETHASONE, EFFICACY, TRANSPLANTATION, POMALIDOMIDE, VENETOCLAX, GENERATION, ANTIBODIES
  • Ankara Üniversitesi Adresli: Evet

Özet

Recurrence of disease due to chemotherapy drug resistance remains a major obstacle to a more successful survival outcome of multiple myeloma (MM). Overcoming drug resistance and salvaging patients with relapsed and/or refractory (R/R) MMis an urgent and unmetmedical need. Several newpersonalized treatment strategies have been developed against molecular targets to overcome this drug resistance. There are several targeted therapeutics with anti-MM activity in clinical pipeline, including inhibitors of anti-apoptotic proteins, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, and various cell therapy platforms. For example, B-cell maturation antigen (BCMA)-specific CAR-T cell platforms showed promising activity in heavily pretreated R/R MM patients. Therefore, there is renewed hope for high-risk as well as R/R MM patients in the era of personalized medicine. (c) 2018 The Authors. Published by Elsevier B.V.